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Mitochondrial Lon protease (LonP1) is a multi-function enzyme that regulates mito-
chondrial functions in several human malignancies, including colorectal cancer (CRC). 
The mechanism(s) by which LonP1 contributes to colorectal carcinogenesis is not fully 
understood. We found that silencing LonP1 leads to severe mitochondrial impairment 
and apoptosis in colon cancer cells. Here, we investigate the role of LonP1 in mito-
chondrial functions, metabolism, and epithelial–mesenchymal transition (EMT) in colon 
tumor cells and in metastasis. LonP1 was almost absent in normal mucosa, gradually 
increased from aberrant crypt foci to adenoma, and was most abundant in CRC. 
Moreover, LonP1 was preferentially upregulated in colorectal samples with mutated p53 
or nuclear β-catenin, and its overexpression led to increased levels of β-catenin and 
decreased levels of E-cadherin, key proteins in EMT, in vitro. LonP1 upregulation also 
induced opposite changes in oxidative phosphorylation, glycolysis, and pentose path-
way in SW480 primary colon tumor cells when compared to SW620 metastatic colon 
cancer cells. In conclusion, basal LonP1 expression is essential for normal mitochondrial 
function, and increased LonP1 levels in SW480 and SW620 cells induce a metabolic 
shift toward glycolysis, leading to EMT.
Keywords: lonP1, mitochondria, bioenergetics, beta-catenin, colorectal cancer, protease
inTrODUcTiOn
LonP1 (also known as Lon or LonP) is one of the main proteases patrolling the mitochondrial matrix. 
Lon is a multi-function enzyme, exerting both proteolytic and chaperone activities, and also binds 
mitochondrial DNA and RNA [reviewed in Ref. (1)]. Main targets of LonP1 proteolytic activity are: 
(i) folded proteins, including 5-aminolevulinic acid synthase, steroidogenic acute regulatory protein, 
mitochondrial transcription factor A, and cytochrome c oxidase 4 isoform 1; (ii) misfolded proteins, 
including glutaminase C; (iii) oxidized proteins, including aconitase and cystathionine β-synthase 
TaBle 1 | Demographic characteristics and tumor stage in samples obtained 
from NM, ACF, Ad, or CRC.
Patient stage age sex
1 NM 84 M
2 NM 85 M
3 NM 78 M
4 NM 86 M
5 NM 84 M
6 NM 46 M
7 NM 52 F
8 NM 82 M
9 NM 46 F
10 NM 86 M
11 NM 43 M
12 NM 82 M
13 ACF 38 F
14 ACF 43 M
15 ACF 46 F
16 ACF 38 F
17 ACF 43 M
18 ACF 43 M
16 Ad 38 F
17 Ad 43 M
18 Ad 46 F
19 Ad 46 F
20 Ad 43 M
21 Ad 43 M
22 CRC 85 M
23 CRC 86 M
24 CRC 46 F
M, male; F, female; NM, normal mucosa; ACF, aberrant crypt foci; Ad, adenoma; CRC, 
colorectal cancer.
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(2–8). Conversely, targets of LonP1 chaperone activity are still 
not known. Initial studies demonstrated that LonP1 was involved 
in mitochondrial maintenance and mitochondrial quality control 
during aging (9, 10). More recent evidence suggests that LonP1 is 
responsible for additional functions critical to tumor progression, 
including metabolic adaptation to hypoxia, protection against 
senescence, and resistance to apoptosis and oxidative stress 
(11–14). Recent data from our group demonstrated that LonP1 
is upregulated in colorectal tumors, and that its downregulation 
or inhibition leads to severe mitochondrial dysfunction and to 
apoptosis (15, 16).
Colorectal cancer (CRC) is the third most common cancer 
worldwide (17). Despite several advances have been made in 
the diagnosis and treatment of CRC over the past decades, 
the overall prognosis still remains poor, and tumor metastasis 
represent a major obstacle to successful treatment (18). The 
epithelial–mesenchymal transition (EMT) is a biologic process 
that enables a polarized epithelial cell to assume a mesenchymal 
cell phenotype through biochemical changes and a number of 
distinct molecular processes (19). Several intracellular signaling 
pathways contribute to EMT, and involve ERK, MAPK, PI3K, 
Akt, Smads, β-catenin (β-ctn), Ras, c-fos, and among others (19). 
The Wnt/β-ctn signaling pathway has a crucial role in the negative 
regulation of E-cadherin, and in the development of EMT and 
CRC metastasis (20). In normal conditions, and in the absence 
of activated Wnt signals, β-ctn is phosphorylated by APC/Axin/
GSK-3β complex and then degraded by the proteasome. When 
Wnt ligands activate Frizzled and LPR receptors, β-ctn is no 
longer phosphorylated and translocates into the nucleus where 
it binds to transcription factors belonging to the family of T-cell 
factor (TCF) and lymphoid enhancer-binding protein, and then it 
activates transcription (21). In CRC, the vast majority of tumors 
have mutations in the key regulatory factors of the Wnt/β-ctn 
pathway and up to 80% present nuclear accumulation of β-ctn 
(20).
Starting from our previous observations, we aimed at inves-
tigating the precise role of LonP1 in colon primary tumor and 
metastasis. In this study, we show that elevated expression of 
LonP1 in CRC tissues is associated with nuclear localization of β-
ctn, and that overexpression of LonP1, in vitro, differently affects 
β-ctn expression in SW480 and SW620 colon cancer cells. We also 
show that LonP1 overexpression differently affects mitochondrial 
functions and bioenergetics in SW480 and SW620 cells.
MaTerials anD MeThODs
cell culture
Four cancer cell lines were used for this study: I407 intestinal epi-
thelial cells, SW480 and RKO colon carcinoma cells, and SW620 
metastatic colon cancer cells. SW480 cells were cultured in 
DMEM high glucose supplemented with 10% fetal bovine serum 
(FBS) and gentamycin. I407, RKO, and SW620 cells were cultured 
in RPMI Glutamax supplemented with 10% FBS and gentamycin. 
Cells were maintained in 5% CO2 atmosphere at 37°C. Culture 
media and reagents were from ThermoFisher Scientific (Eugene, 
OR, USA).
human colorectal Tissues
We have studied a total of 45 patients who underwent surgical 
removal of CRC. Samples used for immunohistochemistry were 
formalin-fixed paraffin-embedded (FFPE) specimens, the other 
samples had been freshly frozen with a passage in liquid nitrogen, 
and then stored at −80°C until use. Tissues were obtained from 
the Department of Diagnostic and Clinical Medicine, and Public 
Health, University of Modena and Reggio Emilia, through an 
institutional review board-approved protocol. Demographic and 
clinical characteristics of patients are reported in Tables 1 and 2.
retroviral Transduction
The pMSCV-Puro empty vector and the pMSCV containing 
the cDNA encoding for Lon protease (hereafter referred to 
as pLonP1) were used to transiently transfect amphotrophic 
Phoenix cell line (15). Cells infected with the empty vector will 
be indicated as pMSCV cells. Retroviral supernatants were used 
to stably transfect I407, RKO, SW480, and SW620 cells, and 
stable transfectants were selected by using 3–4 µg/ml puromycin 
(depending on the cell line), and then maintained in cell medium 
supplemented with 2 µg/ml puromycin.
rna interference
Cells were reverse transfected by using RNAiMAx (Life Technologies 
Corporation) and 10  nM s17901 small interfering RNAs (Life 
Technologies Corporation) against LonP1 mRNA. Then, cells were 
incubated for 72 h, trypsinized, and lysated by using RIPA buffer.
TaBle 2 | Demographic characteristics, tumor stage, Ki-67, β-catenin (β-ctn), E-cadherin (E-cad), p53, LonP1 expression in 21 colorectal cancer samples.
Patient age sex stage site Ki-67 (%) β-ctn e-cad p53 lon ihc lonP1 Wb
1 73 M II Ascending 90 N P + >75% 0.92
2 75 M II Rectum 60 N P + >75% 4.06
3 55 F I Rectum 60 N P + >75% 3.45
4 61 F III Rectum 50 Me P + >75% 2.10
5 59 F II Sigmoid 40 N P + >75% 76.70
6 61 F III Rectum 60 Me P + >75% 4.94
7 83 F III Rectum 60 Me P − >75% 1.37
8 66 F I Rectum 80 N P + >75% 35.30
9 81 F III Ascending 70 Me P + 30–75% 48.85
10 63 M IV Ascending 40 Me P + <30% 0.27
11 72 M III Ascending 60 Me P − 30–75% 2.55
12 88 M I S-R 70 Me P − <30% 0.64
13 80 M IV S-R 40 N P − <30% 3.60
14 71 F II S-R 40 N P − 30–75% 2.53
15 71 M IV Rectum 80 N P − 30–75% 1.17
16 47 M IV S-R 80 N P + 30–75% 7.47
17 62 F IV Ascending 50 Me P − <30% 0.16
18 73 F I Rectum 70 N P + 30–75% 3.56
19 60 F IV Rectum 40 Me P + <30% 0.10
20 56 M III Rectum 60 N P − <30% 0.29
21 75 F I Rectum 70 Me P − 30–75% 1.04
M, male; F, female; Me, membrane; N, nuclear; P, present.
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immunohistochemical analyses
Tumor specimens were taken from patients who underwent 
surgical resection of the large bowel in the period 2010–2015. 
All slides were blindly reviewed by the pathologist (LL). For each 
case, a representative paraffin-embedded block containing tumor 
tissue and normal mucosa, as internal control, was sectioned at 
4 µm. Immunoperoxidase staining was run with the Benchmark 
XT Automatic Staining System (Ventana Roche) with diamin-
obenzidine as chromogen and using the View DAB Detection Kit 
(Roche). At the end of the reaction, slides were counterstained 
with hematoxylin. The following antibodies were used: mouse 
monoclonal antibodies β-ctn (Roche, Basilea, Switzerland), p53 
(Roche), and E-cadherin (Dako, Santa Clara, CA, USA) available 
as pre-diluted commercially preparations; mouse monoclonal 
Ki-67 antibody (MIB-1, Dako, used at 1:100 dilution), and rabbit 
polyclonal LonP1 antibody (Primm, Milan, Italy, used at a 1:500 
dilution). According to previous reports, expression of β-ctn and 
E-cadherin in normal colon epithelium resulted to be restricted 
to cell membrane. Altered expression of β-ctn was contemplated 
when 10% of tumor cells or greater showed nuclear or cytoplasmic 
immunoreactivity. Loss of membrane expression of E-cadherin 
was considered in cases exhibiting either no immunoreactivity 
or 10% of tumor cells or less with positive membranous stain-
ing. Detection of proliferative activity was carried out using an 
anti-Ki-67 antibody, and basal cells of the normal colonic crypts 
were used as internal positive control. Ki-67 labeling index was 
determined by counting the number of positive nuclei for 1,000 
neoplastic cells in 10 consecutive fields chosen randomly in non-
necrotic areas of the tumor.
immunoblotting
Total protein lysate was obtained from cell lines by using RIPA 
buffer and from FFPE tissue as previously described (22). Protein 
concentration was determined by Bradford assay. Proteins were 
then separated in 4–12% or 12% Bolt Bis-Tris precast gels 
(Thermo Fisher Corporation) and transferred onto nitrocel-
lulose membranes. Protein transfer was performed by using 
methanol transfer buffer or by using Trans-Blot Turbo cassettes 
(Bio-Rad Laboratories) with Trans-Blot Turbo blotting system 
(Bio-Rad Laboratories). Rabbit polyclonal anti-LonP1 was a 
custom antibody from Primm (Milan, Italy). Rabbit polyclonal 
anti-β-actin and rabbit polyclonal anti-E-cadherin were from 
Abcam (Cambridge, UK). Rabbit polyclonal to β-ctn, to lactate 
dehydrogenase A (LDHA), to glucose 6-phosphate dehydroge-
nase (G6PD), to N-cadherin, to Akt, to phospho-Akt (Ser473), to 
GSK-3β, to phospho-GSK-3β (Ser9), and to Twist were from Cell 
Signaling Technology (Danvers, MA, USA). Images were acquired 
by using ChemiDoc MP (Bio-Rad Laboratories) and Image Lab 
version 5.2.1 was used to perform densitometric analysis.
immunofluorescence
Cells were grown on coverslips and fixed for 15 min in PBS con-
taining 4% paraformaldehyde. Samples were then washed three 
times with PBS, incubated in PBS containing 0.1% Triton X-100 
for 1 h at room temperature, and blocked by using PBS containing 
3% bovine serum albumin for 1 h. Samples were then incubated 
with PBS containing primary antibody and secondary antibodies 
for 60 and 30  min, respectively. The following antibodies were 
used: rabbit polyclonal anti-β-ctn (Cell Signaling Technology) 
and anti-rabbit Alexa Fluor 647. Images were acquired by using 
a Nikon A1 confocal laser scanning microscope (Nikon, Tokyo, 
Japan).
Transmission electron Microscopy
Cell pellets were fixed in 2.5% glutaraldehyde in Sorensen’s 
Phosphate Buffer 0.1  M pH 7.4 (PB) for 1  h and post-fixed in 
NM ACF Ad CRC0.0
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FigUre 1 | LonP1 expression during colon cancer progression. 
(a) Representative Western blot analysis of LonP1 expression in freshly 
frozen tissue samples from normal mucosa (NM), aberrant crypt foci (ACF), 
colonic adenoma (Ad), and colorectal cancer (CRC). (B) Relative protein level 
of LonP1 in NM, ACF, Ad, and CRC. Data are reported as mean ± SD; 
*P < 0.05 and **P < 0.01.
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1% OsO4 in PB 0.1 M for 1 h, as previously described (23). Then, 
ultrathin sections were cut from Durcupan embedded samples, 
collected on nickel grids, stained with uranyl acetate and lead-
citrate, and then analyzed by using a Zeiss EM 109 Transmission 
Electron Microscope (Zeiss AG, Jena, Germany).
Oxygen consumption rate (Ocr)
The rate of oxygen consumption was assayed with the XF96 
Extracellular Flux Analyzer (Seahorse Biosciences—Agilent 
Technologies, Santa Clara, CA USA). Cells were plated 2  days 
before the experiment, and experiments were performed on 
a confluent monolayer. The number of cells that were plated 
was: 5 × 104/well for SW620-pMSCV and SW620-pLonP1, and 
4 × 104/well for SW480-pMSCV and SW480-pLonP1.
cytofluorimetric analyses
Flow cytometry was used to determine mitochondrial mass, 
mitochondrial membrane potential (MMP), mitochondrial reac-
tive oxygen species (ROS), and glucose transporter (GLUT)-1 
expression. For mitochondrial mass analysis, cells were incubated 
with MitoTracker Green FM (MTG, 200  nM, Thermo Fisher 
Corporation) for 30 min at 37°C. For MMP analysis, cells were 
incubated with tetramethylrhodamine, methyl ester (TMRM, 
200  nM, Thermo Fisher Corporation) for 10  min at 37°C. 
Carbonyl cyanide m-chlorophenyl hydrazine (CCCP, 1 and 
10 µM, Sigma Aldrich) was used to induce mitochondrial mem-
brane depolarization. Mitochondrial superoxide production was 
assessed using MitoSox Red Mitochondrial Superoxide Indicator 
(mtSOX, 5  µM, ThermoFischer Corporation). GLUT-1 expres-
sion was assessed by staining cells with anti-GLUT-1 Alexa Fluor 
488 (Abcam). Data were collected on an Attune NxT (Thermo 
Fisher Corporation) and analyzed with FlowJo software (Tree 
Star, Ashland, OR, USA).
statistical analysis
Quantitative variables were compared with non-parametric 
Mann–Whitney test. Statistical analyses were performed using 
GraphPad 5.0 (Prism, La Jolla, CA, USA). Error bars represent 
SD. A p value <0.05 was considered significant.
resUlTs
lonP1 is Upregulated in crc and is 
associated With Mutated p53 or nuclear 
β-ctn
We previously demonstrated that LonP1 silencing is associated 
with severe mitochondrial dysfunction and apoptosis suscepti-
bility in colon cancer cell lines (22). Herein, we quantified the 
expression of LonP1 during colon cancer progression in fresh 
frozen tissues of ACF, adenoma (Ad), and CRC from a total of 
24 patients, whose demographic and clinical characteristics are 
reported in Table 1. We found that the LonP1 was almost absent 
in normal mucosa, gradually increased from samples of ACF to 
Ad, and was most abundant in samples of CRC (Figures 1A,B). 
In addition, we quantified LonP1 levels in FFPE samples from 
21 patients affected by CRC, whose demographic and clinical 
characteristics are reported in Table 2. Despite inter-individuals 
variations, LonP1 was upregulated in CRC samples compared 
with the normal mucosa counterpart (Figures 2A–D).
In the same FFPE samples, we explored the expression levels of 
EMT-related proteins together with mutated p53 and Ki-67, and 
their association with LonP1. Representative images of immuno-
histochemical staining are reported in Figure 3A. We found that 
LonP1 was preferentially upregulated in colorectal samples with 
mutated p53 or nuclear β-ctn (Figure 3B). No differences were 
observed regarding Ki-67 levels.
lonP1 Modulation is associated With 
changes in β-ctn levels
To investigate the link between LonP1 and EMT in colon, we 
took advantage of four different cell lines, I407, RKO, SW480, 
and SW620 cells. I407 are intestinal epithelial immortalized 
cells. RKO and SW480 are colon carcinoma cells, whereas 
SW620 are metastatic colon cancer cells. Moreover, SW480 
and SW620 represent a primary adenocarcinoma tumor and a 
lymph node metastasis from the same patient, respectively. We 
first established stable LonP1 overexpression in SW480 cells, and 
quantified the levels of several EMT-related proteins, including 
β-ctn, E-cadherin, and N-cadherin. Forced LonP1 expression 
led to increased β-ctn levels, reduced E-cadherin, and increased 
N-cadherin in primary adenocarcinoma cells SW480 (Figure 4A, 
left panels). Similar results were obtained by upregulating 
LonP1 in I407 and RKO cells (Figures S1A,C in Supplementary 
Material). In particular, forced LonP1 expression in these cells led 
to threefold decrease of E-cadherin levels and 2.5-fold increase 
of β-ctn levels in I407 and RKO cells, respectively. I407-pLonP1 
cells also exhibited an elongated, mesenchymal-like morphology, 
which is typically observed in EMT (Figure S1B in Supplementary 
Material). Modulation of β-ctn in SW480-pLonP1 cells was 
also confirmed by fluorescence microscopy (Figure  4B). The 
A B
C
D
FigUre 2 | LonP1 is upregulated in CRC tissues. (a) Representative immunohistochemical staining of LonP1 in paraffin-embedded human colorectal cancer (CRC) 
tissue and patient-matched adjacent normal mucosa. (B) Representative immunohistochemical stainings of LonP1 high or low level overexpression in paraffin-
embedded human CRC tissues. (c) Representative Western blot analysis of LonP1 expression in CRC tissues and normal mucosa. (D) Relative protein levels of 
LonP1 are significantly higher in CRC tissues than in adjacent normal mucosa. Data are reported as mean ± SD (n = 21); *P < 0.05.
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upregulation of LonP1 in SW620 cells, which are metastatic cells, 
led to opposite results (Figure  4A, right panels). Interestingly, 
downregulation of LonP1 in SW620 cells was associated with 
reduced β-ctn expression, increased E-cadherin expression, and 
unchanged N-cadherin in SW620 cells (Figure 4C). Considering 
that Twist is a key regulator of EMT, its expression was analyzed 
in SW480 cells overexpressing LonP1. Twist levels were almost 
twofold increased in SW480-pLonP1 cells, if compared to control 
SW480-pMSCV cells (Figure 4D).
Our study confirmed that LonP1 modulation is associated 
with changes in β-ctn levels and distribution, both in vitro and 
ex vivo, in samples from CRC patients. Considering the central 
role of Akt and GSK-3β in the regulation of β-ctn, we examined 
the phosphorylation status of Akt and GSK-3β, at serine 473 and 
serine 9, respectively. We found that LonP1 overexpression led to 
increased levels of phosphorylated Akt (p-Akt) and phosphoryl-
ated GSK-3β (p-GSK-3β), whereas LonP1 depletion led to a slight 
decrease in p-Akt and p-GSK-3β (Figures 5A,B).
lonP1 impacts glycolysis in colon cancer 
cells
As Akt/GSK-3β signaling pathway plays a critical role in regu-
lating glucose metabolism (24), in SW480 and SW620 cells we 
examined whether forced LonP1 expression had effects on the 
expression of GLUT-1, LDHA, and G6PD. Plasma membrane 
GLUT-1 levels increased in SW480 cells overexpressing LonP1 
(Figure 6A). LDHA levels increased whereas G6PD was almost 
undetectable in SW480 cells overexpressing LonP1 (Figure 6B). 
In this model, glucose 6-phosphate is likely converted into fruc-
tose 6-phosphate, thus entering the glycolytic pathway, rather 
than being converted into glucose 6-phosphate-gluconolactone, 
and entering the pentose phosphate pathway. In SW620 cells, both 
LDHA and G6PD levels increased in the presence of high levels 
of LonP1. We, therefore, analyzed the glycolytic activity of these 
cells by performing a real-time analysis of the extracellular acidi-
fication rate (ECAR, Figure 6C). SW480-pLonP1 cells exhibited 
a higher maximal glycolysis compared with SW480-pMSCV con-
trol cells. Quantitative analysis showed no significant differences 
in basal glycolysis. No changes were observed in SW620 cells.
Considering that LonP1 has been involved in controlling 
tumor bioenergetics by reprogramming mitochondrial func-
tions, we analyzed mitochondrial activity by monitoring OCR. 
Representative curves showed that a difference in mitochondrial 
respiration is present between SW480-pLonP1 and control cells 
(Figure  7A); quantitative analysis showed that basal OCR was 
higher in SW480-pLonP1 cells. Basal and coupled respiration 
as well as maximal respiration and spare respiratory capacity 
were lower in SW620-pLonP1 cells than in SW620-pMSCV cells 
(Figure 7A). Concerning OCR, slight differences were observed 
in I407 or RKO cells in the presence of higher levels of LonP1 
(Figure S2A in Supplementary Material). Since MMP is required 
for production of ATP during oxidative phosphorylation 
(OXPHOS), we analyzed MMP in these cells, by using TMRM. 
MMP was unchanged in SW480-pLonP1 and I407-pLonP1 cells 
(Figure  7A; Figure S2B in Supplementary Material). However, 
both SW480-pLonP1 and control cells were sensitive to CCCP-
induced MMP depolarization (Figure  7B). Interestingly, 
AB
FigUre 3 | LonP1 upregulation is associated with mutated p53 or nuclear β-ctn. (a) Representative immunohistochemical stainings of Ki-67, membrane β-ctn 
(m-βctn), nuclear β-ctn (n-βctn), and p53 in colorectal cancer (CRC) tissues. (B) Association between expression of LonP1, mutated p53, non-mutated p53, 
membrane β-ctn, or nuclear β-ctn in CRC tissues; *P < 0.05.
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SW620-pLonP1 and RKO-pLonP1 cells had depolarized mito-
chondria if compared to SW620-pMSCV and RKO-pMSCV cells, 
respectively (Figure 7B; Figure S2B in Supplementary Material). 
The reduction of MMP in SW620-pLonP1 was maintained when 
cells were treated with 10 µM CCCP. As mitochondrial activity is 
a critical source of ROS, and in particular of anion superoxide, 
we analyzed its levels by using MitoSOX Red Mitochondrial 
Superoxide indicator (MitoSOX). We found that SW480-pLonP1 
cells produced higher levels of anion superoxide compared to 
control cells, at the basal level (Figure 7C). When challenged with 
hydrogen peroxide (H2O2), no differences were observed between 
cells overexpressing LonP1 and control cells (Figure 7C; Figure 
S2C in Supplementary Material). Mitochondrial superoxide 
decreased in SW620-pLonP1 if compared to SW620-pMSCV 
control cells, both at the basal level and after treatment with H2O2 
as pro-oxidant stressor (Figure 7C).
Finally, we asked whether LonP1 modulation had impact 
on mitochondrial mass and mitochondrial ultrastructure. 
Mitochondrial mass was slightly decreased in pLonP1 cells 
(Figure 7D). Analysis of mitochondrial ultrastructure revealed that 
in SW480-pMSCV and SW480-pLonP1 cells mitochondria were 
numerous, occupied most of the cytoplasm and displayed cristae 
fragmentation together with the presence of vacuoles and vesicles 
within the mitochondrial matrix (Figure 7E). SW620-pLonP1 cells 
displayed mitochondrial alterations to a much lesser extent, both in 
number and in shape, with reduced cristae and increased vacuoles, 
and a noteworthy abundance of free ribosomes in the cytoplasm 
(Figure 7E), reasonably due to a massive synthesis of endogenous 
proteins, which correlates with particularly aggressive and undif-
ferentiated neoplasms. The counterpart SW620-pMSCV cells did 
not show altered morphology, or number of mitochondria, whose 
cristae appeared preserved (Figure 7E).
AB
C D
FigUre 4 | LonP1 modulates E-cadherin, N-cadherin, and β-ctn in SW480 colon primary tumor cells and SW620 metastatic tumor cells. (a) Representative 
Western blot analysis and relative protein level of LonP1, β-catenin (β-ctn), E-cadherin (E-cad), N-cadherin (N-cad) in SW480 and SW620 cells overexpressing 
LonP1 (namely pLonP1) and in control cells, i.e., cells stably transfected with empty vector (namely pMSCV). β-actin was used as loading control. Densitometries 
are reported in histograms, and data are reported as mean ± SD (n = 3). *P < 0.05 and **P < 0.01. (B) Representative confocal microscopy image showing β-ctn 
localization in SW480-pMSCV and SW480-pLonP1 cells. Bar, 10 μm. (c) Representative Western blot analysis and relative protein level of LonP1, β-ctn, and  
E-cad SW620, where LonP1 has been downregulated by using small interfering RNAs (siRNAs) against LonP1 mRNA (siLonP1). Control cells were transfected  
with scramble siRNAs and are indicated as siCTRL. Densitometries are reported in histograms, and data are reported as mean ± SD (n = 3). *P < 0.05 and 
**P < 0.01. (D) Representative Western blot analysis and relative protein level of Twist in SW480 cells overexpressing LonP1 (namely pLonP1) and in control cells, 
i.e., cells stably transfected with empty vector (namely pMSCV). β-actin was used as loading control. Densitometries are reported in histograms, and data are 
reported as mean ± SD (n = 3).
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AB
FigUre 5 | LonP1 modulates β-ctn by regulating Akt/GSK3β signaling.  
(a) Representative Western blot analysis and relative protein levels of 
phosphorylated Akt (Ser473), Akt, phosphorylated GSK-3β (Ser9), and 
GSK-3β in SW480 cells overexpressing LonP1. (B) Representative Western 
blot analysis and relative protein levels of phosphorylated Akt (Ser473), Akt, 
phosphorylated GSK-3β (Ser9), and GSK-3β in SW620 downregulating 
LonP1. β-actin was used as loading control. Densitometries are reported in 
histograms, and data are reported as mean ± SD (n = 3). *P < 0.05.
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DiscUssiOn
Several studies have detected frequent alterations in the expres-
sion of mitochondrial proteases in a variety of human tumors, 
suggesting that these proteins may play a role as a novel class of 
tumor promoters or suppressors (14, 25–28). LonP1 is a mito-
chondrial protease and chaperone located in the mitochondrial 
matrix. Initial studies placed LonP1 among “stress response 
proteins,” that is those proteins upregulated in response to cell 
stress (29, 30). More recently, LonP1 has been implicated in the 
control of metabolic networks in mitochondria in melanoma 
cells (14), and in hypoxic adaptation in glioma cells (11). We 
previously showed that: (i) LonP1 is upregulated in several 
cancer cell lines, including RKO, and in CRC tissues if compared 
to adjacent normal mucosa, and that (ii) colon cancer cells with 
low levels of LonP1 displayed reduced levels of OXPHOS com-
plexes, reduced OCR, and increased mitochondrial ROS and 
highly fragmented and altered mitochondria (22). However, the 
precise role of LonP1 in colon cancer progression has not been 
clarified.
In this study, we analyzed the expression of LonP1 in different 
stages of colon cancer and the consequences of its upregulation 
at the mitochondrial and cellular level. The first observation is 
that LonP1 expression gradually increases in normal mucosa, 
ACF, Ad, and CRC. The fact that LonP1 levels are higher 
in CRC could suggest a potential role for LonP1 in EMT, an 
early step in the formation of metastasis (31). We observed 
high levels of LonP1 in CRC tissues with nuclear localization 
of β-ctn or in CRC tissues with mutated p53. It is noteworthy 
that both β-ctn and p53 are directly involved in EMT: β-ctn/
TCF4 complex induces EMT through transcription activation 
of ZEB1 (32), whereas p53 regulates the transcription of genes 
that are involved in pathways that suppress tumor metastasis, 
and mutations of p53 can precede metastasis (33). Although 
previous studies have reported that LonP1 overexpression is 
associated with decreased E-cadherin, increased N-cadherin 
and vimentin, a possible link between LonP1 and β-ctn has 
never been reported (14, 34).
β-ctn is a key component of the Wnt signaling pathway, and 
acts as negative regulator of E-cadherin in the induction of EMT. 
In the absence of Wnt stimulation, cytoplasmic β-ctn is phos-
phorylated by the APC/Axin/GSK-3β complex, and is degraded 
into the proteasome (35). We reported that LonP1 modulation 
led to important changes in total β-ctn levels, in several colon 
cancer cell lines. To understand which pathway was involved in 
LonP1 regulation of β-ctn, we investigated the phosphorylation 
status of Akt and GSK-3β, as Akt can phosphorylate, and thus 
inactivate GSK-3β (36). To explore the role of LonP1 in Akt/GSK-
3β signaling pathway, SW480 and SW620 colon carcinoma cell 
lines were chosen as models since they are derived from primary 
and secondary tumors resected from the same patient, that makes 
them a valid tool to investigate changes in colon cancer progres-
sion (37). In SW480 cells, the upregulation of an oncoprotein or 
a protein-like LonP1 would lead to EMT. On the contrary, the 
downregulation of the same protein in SW620 cells, which are 
already metastatic, would leave unchanged the mesenchymal 
phenotype. Indeed, forced LonP1 expression in SW480 led to 
increased levels of mesenchymal markers, and LonP1 upregula-
tion was associated with increased phosphorylation of Akt and 
GSK-3β, thus highlighting a role for LonP1 as a regulatory factor 
in the Wnt/β-ctn pathway. Accordingly, it was interesting to 
observe that Twist, a key promoter of cancer progression, was 
involved in EMT. A number of studies have suggested that Twist 
induces EMT via AKT/GSK-3β/β-catenin pathways, among 
 others (38).
While previous studies regarding LonP1 and cancer reported 
that LonP1 induced EMT through ROS-dependent MAPK 
signaling, at least in 293 T  cells, we found that mitochondrial 
ROS were not implicated in EMT induction (34). Rather, other 
mechanisms could be involved, including the alteration of 
pathways involved in the rearrangement of cellular metabolism. 
It has been reported that LonP1 controls tumor bioenergetics 
by remodeling subunits of electron transport chain (14). We 
found that in colon cancer cells LonP1 can influence glycolytic 
AB
C
FigUre 6 | LonP1 modulates glycolytic activity in colon cancer cells. (a) Representative histograms showing glucose transporter (GLUT)-1 expression in 
SW480-pMSCV, SW480-pLonP1, SW620-pMSCV, and SW620-pLonP1 cells. Quantitative analysis is reported on the right and shows the median fluorescence 
intensity of plasma membrane GLUT-1 levels, as revealed by flow cytometry. (B) Representative Western blot analysis and relative protein levels of phosphorylated 
lactate dehydrogenase A and glucose 6-phosphate dehydrogenase in SW480 and SW620 cells overexpressing LonP1. β-actin was used as loading control. 
Densitometries are reported in histograms, and data are reported as mean ± SD (n = 3). *P < 0.05. (c) Representative traces and quantitative analysis of 
extracellular acidification rate in indicated cells. Subsequent injections of glucose (Glu), oligomycin (Oligo), and 2-deoxy-glucose were performed as indicated.
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activity together with mitochondrial activity. Alongside, effects 
of LonP1 overexpression have been observed in the initial steps 
of pentose phosphate pathway, which is required for the synthesis 
of ribonucleotides from glucose and is a major source of nico-
tinamide adenine dinucleotide phosphate. Pentose pathway is 
important for redox balance and anabolism, and seems indeed 
to be promoted in SW620-pLonP1 cells. In SW620-pLonP1 
cells, glucose could be redistributed to alternative pathways, 
such as the pentose pathway, to support growth and survival 
of these cells, which were characterized by reduced OXPHOS. 
In agreement with this observation, the pentose phosphate 
pathway was strongly decreased in SW480-pLonP1, where 
OXPHOS was almost unchanged. Despite the fact that SW480 
and SW620 have the same genetic background, characterized 
by mutations in KRAS and TP53, overexpression of LonP1 has 
dramatically different consequences on mitochondrial function, 
bioenergetics, and in malignant transformation. While LonP1 
does not influence OCR or mitochondrial functions in SW480 
cells, its overexpression in SW620 cells determines a reduction 
of OCR and depolarization of mitochondrial membrane. We 
would expect that mitochondrial membrane depolarization 
resulted in increased ROS production, but this was not case. We 
rather observed a decrease in mitochondrial anion superoxide 
in SW620-pLonP1 when compared with SW620-pMSCV cells. 
The analysis of morphology and ultrastructure of mitochondria 
confirmed that overexpression of LonP1 has a stronger impact on 
SW620 than SW480 cells.
In conclusion, our findings demonstrate a role for LonP1 in 
the regulation of EMT via GSK-3β/β-ctn and modifications in 
cellular metabolism, suggesting that changes in LonP1 expres-
sion and EMT in CRC are likely not two independent, concurrent 
phenomena, but might be functionally linked.
DE
FigUre 7 | LonP1 slightly modulates mitochondrial activity in colon cancer cells. (a) Representative traces and quantitative analysis of the oxygen consumption 
rate in indicated cells. Subsequent injections of oligomycin (Oligo), mitochondrial decoupler carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP), complex I 
inhibitor rotenone (Rot), and complex III inhibitor (AntA) were performed as indicated; *P < 0.05. (B) Mitochondrial membrane potential quantification was assayed 
by tetramethyl rodhamine methyl esther (TMRM) in the presence or absence of CCCP in indicated cells. Data are expressed as percentage of increase in median 
fluorescence intensity (MFI) and represented the mean ± SD (n = 4); *P < 0.05. (c) Mitochondrial anion superoxide quantification as assayed by MitoSOX Red 
Mitochondrial Superoxide Indicator (mitoSOX) in the presence or absence of hydrogen peroxide in indicated cells. Data are expressed as percentage of increase in 
MFI and represented the mean ± SD (n = 4). (D) Mitochondrial mass quantification as assayed by Mitotracker Green in indicated cells. Data are expressed as 
percentage of increase in MFI and represented the mean ± SD (n = 4); *P < 0.05. (e) Representative transmission electron microscopy images of indicated cells. 
Scale bars, 1 µm.
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FigUre s1 | LonP1 modulates E-cadherin, N-cadherin, and β-ctn in I407 and 
RKO cells. (a) Representative Western blot analysis and relative protein level of 
LonP1, β-catenin (β-ctn), E-cadherin (E-cad), N-cadherin (N-cad) in I407 cells 
overexpressing LonP1 (namely pLonP1) and in control cells, i.e., cells stably 
transfected with empty vector (namely pMSCV). β-actin was used as loading 
control. Densitometries are reported in histograms, and data are reported as 
mean ± SD (n = 3). *P < 0.05 and **P < 0.01. (B) Representative phase 
contrast images of I407 cells overexpressing LonP1 (pLonP1) and control cells 
(pMSCV). Scale bar, 10 µm. (c) Representative Western blot analysis and 
relative protein level of LonP1, β-catenin (β-ctn), E-cadherin (E-cad), and 
N-cadherin (N-cad) in RKO cells overexpressing LonP1 (namely pLonP1) and in 
control cells, i.e., cells stably transfected with empty vector (namely pMSCV). 
β-actin was used as loading control. Densitometries are reported in 
histograms, and data are reported as mean ± SD (n = 3). *P < 0.05 and 
**P < 0.01.
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potential quantification as assayed by tetramethyl rodhamine methyl esther 
(TMRM) in the presence or absence of CCCP in indicated cells. Data are 
expressed as percentage of increase in median fluorescence intensity (MFI) and 
represented the mean ± SD (n = 3); *P < 0.05. (c) Mitochondrial anion 
superoxide quantification as assayed by MitoSOX Red Mitochondrial Superoxide 
Indicator (mitoSOX) in the presence or absence of hydrogen peroxide in indicated 
cells. Data are expressed as percentage of increase in MFI and represented the 
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